Showing 17,561 - 17,580 results of 29,617 for search '(( 12 wt decrease ) OR ( 50 ((((mean decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 0.94s Refine Results
  1. 17561
  2. 17562
  3. 17563
  4. 17564
  5. 17565

    Figure S1 - E2A Predicts Prognosis of Colorectal Cancer Patients and Regulates Cancer Cell Growth by Targeting miR-320a by Ao Huang (508797)

    Published 2014
    “…Right: Change of E2A expression in SW480 cells after transfection of shE2A, E12 or E47: shE2A reduced the expression of E2A in SW480, while E12 and E47 increased E2A expression in SW480/shE2A cells, relative to the controls; (B) Transfection of E12 or E47 inhibited SW480/WT cell growth; (C) E2A regulates cell growth in NCM460 cells; (D) Transfection of E12 or E47 increased G<sub>0</sub>/G<sub>1</sub> phase of SW480/WT cells and decreased the S phase; (E) E2A regulates cell cycle progression in NCM460 cells; (F) Transfection of E12 or E47 upregulated the expression of miR-320a, compared to negative control. …”
  6. 17566
  7. 17567

    Metformin does not further increase the median lifespan of DR-constitutive mutant eat-2, and metformin treatment triggers several DR phenotypes in wild-type <i>C. elegans</i> witho... by Brian Onken (86790)

    Published 2010
    “…<p><b>A.</b> Survival curves of <i>eat-2(ad1116)</i> mutants raised on 0 mM, 1 mM, 10 mM, and 50 mM metformin plates at 20°C. …”
  8. 17568

    Regulation of MCF-7 mammosphere formation by breast cancer promoters and metformin. by Ji-Won Jung (194917)

    Published 2011
    “…On the other hand, metformin treatment decreased MCF-7 proliferation (mean ± SD, n = 3). *, <i>P</i><0.05; **, <i>P</i><0.01; ***, <i>P</i><0.001. …”
  9. 17569
  10. 17570

    Variation of average codeword length (ACL) by number of edges. by Dario Elias (8882177)

    Published 2020
    “…A positive variation indicates a decrease in the ACL. …”
  11. 17571

    Complementary conditioning measures across the clinical study groups. by Gabriela Ribeiro (4748373)

    Published 2024
    “…CS<sup>+</sup> (F<sub>(1, 50)</sub> = 5.2, <i>P</i> = 0.03), with a no significant effects for Group (F<sub>(2, 50)</sub> = 0.1, <i>P</i> = 0.9) nor for interaction (F<sub>(2, 50)</sub> = 0.9, <i>P</i> = 0.4). …”
  12. 17572
  13. 17573
  14. 17574
  15. 17575
  16. 17576

    Scutellarin’s Cardiovascular Endothelium Protective Mechanism: Important Role of PKG-I<i>α</i> by Lin Li (28817)

    Published 2015
    “…The activation of PKG–1α was then studied using targeted proteomic analysis (MRM-MS) checking the phosphorylation state of the autophosphorylation domain (aa42-94). Significant decrease in phosphorylation of PKG-Iα at Ser50, Ser72, Ser89 was induced by HR injury while SCU treatment significantly increased the phosphorylation of PKG-Iα, not only at Ser50, Ser72 and Ser89, but also at Ser44 and Thr58 (two novel phosphorylation domains). …”
  17. 17577

    Histone deacetylase (HDAC) inhibitor assessment. by Ilona Tkachyova (343715)

    Published 2016
    “…ITF 2357, an HDAC inhibitor which is structurally and functionally similar to SAHA, produced a dose-response curve with IC<sub>50</sub> of 0.2 μM. …”
  18. 17578

    Plk1 inhibition suppresses the clonogenic potential of SUM149 and SUM159. by Antonio Giordano (55096)

    Published 2019
    “…(B) EC<sub>50</sub> was defined as 50% colony inhibition. Single agents EC<sub>50</sub> were reported for each TNBC cell line and drug. …”
  19. 17579

    Image2_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg by Cristina López (2841392)

    Published 2024
    “…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”
  20. 17580

    Image1_Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.jpeg by Cristina López (2841392)

    Published 2024
    “…</p>Results<p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. …”